Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

4.87
-0.4500-8.46%
Post-market: 4.86-0.0100-0.21%19:51 EDT
Volume:4.16M
Turnover:20.92M
Market Cap:419.85M
PE:-1.29
High:5.35
Open:5.17
Low:4.87
Close:5.32
52wk High:19.11
52wk Low:3.95
Shares:86.21M
Float Shares:60.67M
Volume Ratio:0.22
T/O Rate:6.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:2.52
PE(LYR):-1.54

Loading ...

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Dow Jones
·
Yesterday

Sweden's SynAct Pharma Q2 Net Loss Narrows on Lower Expenses

Reuters
·
Aug 20

Analyst Maintains Buy on Duravyu, Cutting Price Target to $20 Amid LUCIA Trial Binary Risk

TIPRANKS
·
Aug 19

Iridex Q2 Revenue Falls as Retina Sales Decline

Reuters
·
Aug 19

EyePoint Director Karen Zaderej Reports Purchase of 10,600 Shares Worth $52,258

Reuters
·
Aug 19

EyePoint is Maintained at Buy by Citigroup

Dow Jones
·
Aug 19

EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says

MT Newswires Live
·
Aug 18

U.S. Stocks on the MOVE-Dynatrace, Duolingo, Baidu Inc

Reuters
·
Aug 18

EyePoint Inc : H.c. Wainwright Cuts to Neutral from Buy

THOMSON REUTERS
·
Aug 18

EyePoint (EYPT) Following LUGANO Data Is The Undervalued Narrative Still Intact

Simply Wall St.
·
Aug 18

EyePoint Falls After Experimental Drug Misses Goal, Brokerages Cut Ratings

Reuters
·
Aug 18

EyePoint Inc : Jefferies Cuts Target Price to $8 from $30

THOMSON REUTERS
·
Aug 18

EyePoint Inc : JP Morgan Cuts to Neutral from Overweight

THOMSON REUTERS
·
Aug 18

EyePoint downgraded to Sector Perform from Outperform at RBC Capital

TIPRANKS
·
Aug 18

NASD Most Active Issues

Dow Jones
·
Aug 18

Mobile Healthcare Provider DocGo's Q2 Revenue Misses on Wind-Down of Migrant Programs

Reuters
·
Aug 18

U.S. Small Caps Drop; EyePoint Posts Biggest Loss

Dow Jones
·
Aug 18

Laidlaw trims EyePoint target, still sees high change of approval

TIPRANKS
·
Aug 18

Top Midday Decliners

MT Newswires Live
·
Aug 18

B. Riley views EyePoint study miss as positive for 4D Molecular

TIPRANKS
·
Aug 18